CASE REPORT
Protective antigen domain 4 of Bacillus anthracis as a candidate for use as vaccine for anthrax
 
More details
Hide details
1
Biological Threats Identification and Countermeasure Center of the General Karol Kaczkowski Military Institute of Hygiene and Epidemiology, Puławy, Poland
2
Department of Didactics and Medical Simulation, Medical University, Lublin, Poland
 
KEYWORDS:
TOPICS:
ABSTRACT:
Existing research for using the protective antigen (PA) of Bacillus anthracis as a vaccine component shows that protection against anthrax may be obtained using fragments of this protein. The aim of the research is to check whether the selected protein fragment of the protective antigen (domain 4) encoded by an appropriate nucleotide sequence of gene pag of B. anthracis, was expressed in the bacterial system of E. coli. In order to examine the selected sequence of the pag gene, a PCR reaction and a highly effective TOPO cloning strategy were used, followed by purification of the recombinant proteins and their detection by a western-blot method. In the planning of the PA4 antigen expression a higher level of effectiveness in production of small protein – domain 4 – was anticipated. As a result, the 139 amino acids protein fragment of B. anthracis PA (domain 4) was isolated. The research may have found the basis for in vivo research aimed at finding potential anthrax vaccine components.
CORRESPONDING AUTHOR:
Dorota Żakowska   
Biological Threats Identification and Countermeasure Center of the General Karol Kaczkowski Military Institute of Hygiene and Epidemiology, Puławy, Poland, Lubelska 2 St., 24-100 Puławy, Poland
 
REFERENCES (17):
1. Brossier F, Mock M. Toxins of Bacillus anthracis. Toxicon. 2001; 39(11): 1747–1755.
2. Gierczyński R. Diagnostics and molecular epidemiology of Bacillus anthracis. Post Mikrob. 2010; 49(3): 165–172 (in Polish).
3. Varshney A, Goel AK. Development of recombinant domains of protective antigen of Bacillus anthracis and evaluation of their immune response in mouse model for use as vaccine candidates for anthrax. J Bioterror Biodef. 2016; 7: 147, doi: 10.4172/2157-2526.1000147.
4. Welkos SL, Lowe JR, Eden-McCutchan F, Vodkin M, Leppla SH, Schmidt JJ. Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis. Gene. 1988; 69(2): 287–300.
5. Flik-Smith HC, Walker NJ, Gibson P, Bullifent H, Hayward S, Miller J, et al. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun. 2002; 70(3): 1653–1656.
6. Petosa C, Collier RJ, Klimpel KR, Leppla SH, Liddington RC. Crystal structure of the anthrax toxin protective antigen. Nature. 1997; 385(6619): 833–838.
7. Ivins BE, Welkos SL. Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol. 1988; 4(1): 12–19.
8. Turnbull PC. Anthrax vaccines: past, present and future. Vaccine. 1991; 9(8): 533–539.
9. Chomiczewski K. Vaccines against anthrax. Wakcynologia, Bielsko-Biała α–Medica Press; 2005; 394–397 (in Polish).
10. Suryanarayana N, Vanlalhmuaka, Mankere B, Verma M, Thavachelvam K, Tuteja U. Soluble expression and characterization of biologically active Bacillus anthracis protective antigen in Escherichia coli. Mol Biol International. 2016; 2016: 1–11, http://dx.doi.org/10.1155/2016....
11. Żakowska D, Kocik J, Bartoszcze M. Selected research problems of anthrax vaccine development. Prz Epidemiol. 2009; 63(4): 505–512 (in Polish).
12. Krishnanchettiar S, Sen J, Caffrey M. Expression and purification of the Bacillus anthracis protective antigen domain 4. Protein Expr Purif. 2003; 27(2): 325–330.
13. Willhite DC, Blanke SR. Soluble expression and one-step purification of recombinant Bacillus anthracis protective antigen. Prot Pept Let. 1998; 5(5): 273–278.
14. Nuc P, Nuc K. Recombinant protein production in Escherichia coli. Post Bioch. 2006; 52(4): 448–456 (in Polish).
15. Pavan ME, Pavan EE, Cairo FM, Pettinari MJ. Expression and refolding of the protective antigen of Bacillus anthracis: A model for high-throughput screening of antigenic recombinant protein refolding. Rev Argent Microbiol. 2016; 48(1): 5–14.
16. Rezaee M, Honari H, Kooshk MRA. Cloning, expression and purification of binding domains of lethal factor and protective antigen of Bacillus anthracis in Escherichia coli and evaluation of their related murine antibody. Mol Biol Rep. 2014; 41(4): 2445–2452.
17. Abboud N, Casadevall A. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background. Clin and Vaccine Immunol 2008; 15(7): 1115–1123.
eISSN:1898-2263
ISSN:1232-1966